HER2-Positive Breast Cancer: A Guide Through An Evolving Treatment Landscape
The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for their patients with HER2-positive breast cancer.
Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC
This program is intended for oncologists, physician assistants, nurses, pharmacists, and other clinicians involved in the management of patients with HER2-positive breast cancer.
Upon completion of this activity, participants should be able to:
- Plan optimal adjuvant and/or extended adjuvant treatment strategies for patients with HER2-positive early-stage breast cancer
- Integrate recent advances and available clinical data to optimally sequence HER2-targeted agents in the treatment of HER2-positive metastatic breast cancer
- Apply the latest clinical evidence on HER2-targeted agents to treat patients with HER2-low–expressing tumors
- Plan effective therapy for patients with HER2-positive metastatic breast cancer and CNS metastases
- Evaluate emerging research, the mechanisms of action, and the role of novel HER2-targeted therapies in clinical investigation for patients with HER2-positive metastatic breast cancer
Jame Abraham, MD, FACP
Chairman, Department of Hematology and Medical Oncology
Taussig Cancer Institute
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Hope Rugo, MD
Clinical Professor of Medicine
UCSF Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California
Sara Tolaney, MD, MPH
Assistant Professor of Medicine
Harvard Medical School
Susan F. Smith Center for Women's Cancer
Director of Clinical Trials, Breast Oncology
Director of Breast Immunotherapy Clinical Research
Breast Oncology Program
Dana-Farber Cancer Institute
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).
Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.
NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
The faculty, NCCN staff, and CCO staff reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Jame Abraham, MD, FACP, has no relevant financial relationships to disclose.
Hope S. Rugo, MD, has disclosed that she has received funds for research support (paid to her institution) from Daichi Sankyo, Eisai, Genentech, Immunomedics, Lilly, Macrogenics, Merck, Novartis, OBI, Odonate, Pfizer, SeaGen, and Sermonix; consulting fees from Mylan, Puma, and Samsung; and other financial material support from AstraZeneca, Daiichi Sankyo, Macrogenics, Mylan, Merck, Novartis, and Pfizer.
Sara Tolaney, MD, MPH, has disclosed that she has received funds for research support from AstraZeneca, Bristol-Myers Squibb, Cyclacel, Eisai, Exelixis, Genentech/Roche, Immunomedics/Gilead, Lilly, Merck, Nektar, Novartis, Odonate, Pfizer, Sanofi, and SeaGen; and consulting fees from AstraZeneca, Athenex, Bristol-Myers Squibb, Cytomx, Daiichi Sankyo, Eli Lilly, Eisai, Genentech/Roche, Immunomedics/Gilead, Kyowa Kirin Pharmaceuticals, Nektar, Novartis, Odonate, OncoPep, Pfizer, Puma, Samsung Bioepsis, Sanofi, and SeaGen.
The activity planning staff listed below disclose no relevant financial relationships:
CCO: Terrence Fagan; Timothy A. Quill, PhD; Petra Cravens, PhD; Kevin Obholz, PhD; June Wasserstrom
NCCN: Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Karen Kanefield; Kathy Ann Smith, CHCP
The CCO planning staff listed below discloses the following relevant financial relationships:
Jim Mortimer: spouse/partner has ownership interest (stock) in AstraZeneca
The NCCN clinical staff listed below discloses no relevant financial relationships:
Rashmi Kumar, PhD
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 1.5 contact hours.
NCCN designates this application-based continuing education activity for 1.5 contact hours (0.15 CEUs) of continuing education credit. UAN: JA4008196-0000-21-017-L01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
- 1.50 AAPA Category 1 CME credit
- 1.50 ACPE contact hours
- 1.50 AMA PRA Category 1 Credit™
- 1.50 ANCC contact hours
- 1.50 Participation